Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Center Statistics Reveal Drop In Complaints – Ombudsman Report

This article was originally published in The Gray Sheet

Executive Summary

CDRH Ombudsman Les Weinstein received 47% fewer complaints last year than in 2001, but 24% more disputes, according to the 1ombudsman's annual report

You may also be interested in...



Device Center Disputes And Complaints Increased In 2003 – Ombudsman

The number of complaints received by CDRH Ombudsman Les Weinstein roughly tripled last year

Device Center Disputes And Complaints Increased In 2003 – Ombudsman

The number of complaints received by CDRH Ombudsman Les Weinstein roughly tripled last year

Pro-Industry Dispute Decisions Continue To Outnumber CDRH-Favored Results

Dispute resolution decisions at the Center for Devices and Radiological Health are twice as likely to favor industry than FDA, according to Ombudsman Les Weinstein

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel